PT-141
Melanocortin receptor agonist
A melanocortin-receptor agonist, FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Studied for arousal via central nervous-system pathways rather than the vascular route.
- Half-life
- Approximately 2.7 hours
- Typical dose
- 1.75 mg
